All In Biotech

Drug Trial Radar · NCT07670884

A Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Tablets in Overweight or Obese Subjects

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase III Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Tablets in Overweight or Obese Subjects

Last checked: Nov 19, 2026Latest source record: Aug 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 675 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

675

Planned (sponsor's estimate)

Start

Jul 24, 2026

Primary completion

Oct 31, 2027

Study completion Nov 30, 2027

Sponsor

Sponsor type
Industry
First posted
Jun 26, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study aims to evaluate the efficacy and safety of HRS9531 tablets compared with placebo in reducing body weight in overweight or obese subjects after 52 weeks of treatment.

Conditions

  • Chronic Management of Body Weight

Interventions

  • HRS9531 TabletDrug

    HRS9531 tablet.

  • HRS9531 Tablet PlaceboDrug

    HRS9531 tablet placebo.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage change from baseline in body weight after 52 weeks of treatmentTime frame: After 52 weeks of treatment.
  2. Proportion of subjects with weight loss of ≥ 5% from baseline in body weight after 52 weeks of treatmentTime frame: After 52 weeks of treatment.

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Henan Provincial People's Hospital

    Zhengzhou, Henan, China · Recruiting

  • Nanjing Drum Tower hospital

    Nanjing, Jiangsu, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.